Nuvectis Pharma (NVCT) said Thursday its phase 1b trial to evaluate NXP800 in patients with platinum-resistant ARID1a-mutated ovarian cancer demonstrated antitumor activity, including tumor shrinkage.
"The antitumor activity observed despite patients' advanced disease and extensive pre-treatment, while controlling for thrombocytopenia, is promising," said Ron Bentsur, CEO of Nuvectis.
The company expects to report additional clinical data from the trial in Q2 of next year, Bentsur said.
NXP800 was granted orphan drug designation by the US Food and Drug Administration in August.
Nuvectis Pharma shares were 54% lower in recent premarket trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。